Table 2.
Univariate analysis of 31 features used for machine learning models.
| Variable | Overall | 1-year survivors (n=677) | death within the 1st year (n=232) | p-value |
|---|---|---|---|---|
| Age at alloHCT | 58.5 (48.3–66.1) | 57.0 (45.3–64.8) | 63.3 (54.1–68.7) | <0.001 |
| Donor Age | 33.0 (25.0–47.0) | 32.0 (25.0–46.0) | 36.0 (27.0–49.0) | 0.003 |
| TCI score | 2.5 (2.5–3.5) | 2.5 (2.5–3.5) | 2.5 (2.5–2.5) | 0.012 |
| Performance status at alloHCT | 90.0 (80.0–90.0) | 90.0 (80.0–90.0) | 80.0 (80.0–90.0) | <0.001 |
| Disease Features | ||||
| AML | 411/909 (45.2%) | 304/677 (44.9%) | 107/232 (46.1%) | 0.748 |
| MDS | 96/909 (10.6%) | 81/677 (12.0%) | 15/232 (6.5%) | 0.019 |
| Lymphoma | 124/909 (13.6%) | 68/677 (10.0%) | 56/232 (24.1%) | <0.001 |
| Active disease at alloHCT | 554/909 (60.9%) | 382/677 (56.4%) | 172/232 (74.1%) | <0.001 |
| Lymphocytes | ||||
| pre-transplant B-cells (cells/µl) | 24.0 (2.0–90.0) | 32.0 (3.0–99.0) | 10.5 (1.0–69.5) | <0.001 |
| pre-transplant CD4+ T cells (cells/µl) | 343.0 (209.0–524.0) | 375.0 (226.0–541.0) | 280.5 (167.5–435.4) | <0.001 |
| pre-transplant NK cells (cells/µl) | 89.0 (40.0–158.0) | 93.0 (41.0–166.0) | 77.0 (38.0–138.2) | 0.071 |
| pre-transplant CD8+ T cells (cells/µl) | 249.0 (137.0–442.0) | 264.0 (151.0–445.0) | 201.2 (109.5–387.2) | 0.005 |
| Laboratory values | ||||
| LDH (U/L) | 200.0 (169.0–271.5) | 196.5 (169.0–257.0) | 222.0 (169.8–321.9) | 0.003 |
| Platelets (K/µL) | 111.0 (42.0–185.5) | 122.0 (49.0–199.0) | 76.2 (29.4–159.5) | <0.001 |
| Creatinine (mg/dL) | 0.9 (0.7–1.0) | 0.8 (0.7–1.0) | 0.9 (0.8–1.1) | 0.002 |
| Albumin (g/dL) | 4.1 (3.8–4.3) | 4.1 (3.8–4.4) | 3.8 (3.5–4.2) | <0.001 |
| CRP (mg/L) | 4.2 (0.0–12.5) | 3.5 (0.0–10.0) | 8.0 (1.5–20.0) | <0.001 |
| ALT (GPT) (U/L) | 25.0 (16.0–42.5) | 26.0 (16.0–42.0) | 25.0 (15.2–45.0) | 0.75 |
| GvHD prophylaxis | ||||
| ATLG | 500/909 (55.0%) | 391/677 (57.8%) | 109/232 (47.0%) | 0.004 |
| PT-CY | 73/909 (8.0%) | 49/677 (7.2%) | 24/232 (10.3%) | 0.133 |
| CyA | 859/909 (94.5%) | 640/677 (94.5%) | 219/232 (94.4%) | 0.937 |
| Everolimus | 52/909 (5.7%) | 37/677 (5.5%) | 15/232 (6.5%) | 0.571 |
| MPA | 644/909 (70.8%) | 489/677 (72.2%) | 155/232 (66.8%) | 0.117 |
| Methotrexate | 84/909 (9.2%) | 69/677 (10.2%) | 15/232 (6.5%) | 0.091 |
| Alemtuzumab | 184/909 (20.2%) | 119/677 (17.6%) | 65/232 (28.0%) | <0.001 |
| Patient/donor | ||||
| Patient Gender Male | 545/909 (60.0%) | 396/677 (58.5%) | 149/232 (64.2%) | 0.124 |
| Donor Gender Male | 576/909 (63.4%) | 426/677 (62.9%) | 150/232 (64.7%) | 0.637 |
| Mismatch | 237/909 (26.1%) | 154/677 (22.7%) | 83/232 (35.8%) | <0.001 |
| CMV high risk (R+) | 504/909 (55.4%) | 372/677 (54.9%) | 132/232 (56.9%) | 0.606 |
| CMV int. risk (D+/R-) | 94/909 (10.3%) | 63/677 (9.3%) | 31/232 (13.4%) | 0.08 |
| CMV low risk (D-/R-) | 311/909 (34.2%) | 242/677 (35.7%) | 69/232 (29.7%) | 0.096 |
Comparison between survivors and non-survivors one year after alloHCT. Continuous variables are reported as median (interquartile range; 25th-75th percentile) and compared using the Mann-Whitney U test. Categorical variables are presented as count/total (percentage) and compared using the chi-square test.